



Molina Healthcare of Nebraska, Provider Notice

Termination of Federal Rebate Agreement for Xifaxan (Rifaximin)

09/29/2025

Molina Healthcare is alerting providers to the termination of the federal rebate agreement for Xifaxan (rifaximin).

Effective October 1, 2025, claims for Xifaxan (rifaximin) may reject. There are no other rifaximin products with a federal rebate. If members meet criteria for Early and Periodic Screening, Diagnostic, and Treatment services (EPSDT), providers should request prior authorization (PA) via EPSDT. Members may also be eligible for the manufacturer patient assistance program.

Resources for patient assistance program:

- General Information: <https://www.bauschhealthpap.com/>
- Application: <https://www.bauschhealthpap.com/siteassets/pdf/docs/bh-pap-application-pap-medicaid.pdf>

The prior authorization forms and our Preferred Drug List can be found here:

www.molinahealthcare.com/providers/ne/medicaid/resources/pharmacy.aspx

Thank you for your continued service to Molina members.

If you have general questions about this communication, please contact our Provider Relations Team at NEProviderRelations@MolinaHealthcare.com.